128 related articles for article (PubMed ID: 33823990)
21. The association of BRCA1 and BRCA2 mutations with prostate cancer risk, frequency, and mortality: A meta-analysis.
Oh M; Alkhushaym N; Fallatah S; Althagafi A; Aljadeed R; Alsowaida Y; Jeter J; Martin JR; Babiker HM; McBride A; Abraham I
Prostate; 2019 Jun; 79(8):880-895. PubMed ID: 30900310
[TBL] [Abstract][Full Text] [Related]
22. BRCA carriers have similar reproductive potential at baseline to noncarriers: comparisons in cancer and cancer-free cohorts undergoing fertility preservation.
Gunnala V; Fields J; Irani M; D'Angelo D; Xu K; Schattman G; Rosenwaks Z
Fertil Steril; 2019 Feb; 111(2):363-371. PubMed ID: 30527950
[TBL] [Abstract][Full Text] [Related]
23. Impact of a paternal origin of germline BRCA1/2 mutations on the age at breast and ovarian cancer diagnosis in a Southern Swedish cohort.
Ellberg C; Jernström H; Broberg P; Borg Å; Olsson H
Genes Chromosomes Cancer; 2015 Jan; 54(1):39-50. PubMed ID: 25251729
[TBL] [Abstract][Full Text] [Related]
24. Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and meta-analysis.
Moorman PG; Havrilesky LJ; Gierisch JM; Coeytaux RR; Lowery WJ; Peragallo Urrutia R; Dinan M; McBroom AJ; Hasselblad V; Sanders GD; Myers ER
J Clin Oncol; 2013 Nov; 31(33):4188-98. PubMed ID: 24145348
[TBL] [Abstract][Full Text] [Related]
25. Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study.
Eisen A; Lubinski J; Klijn J; Moller P; Lynch HT; Offit K; Weber B; Rebbeck T; Neuhausen SL; Ghadirian P; Foulkes WD; Gershoni-Baruch R; Friedman E; Rennert G; Wagner T; Isaacs C; Kim-Sing C; Ainsworth P; Sun P; Narod SA
J Clin Oncol; 2005 Oct; 23(30):7491-6. PubMed ID: 16234515
[TBL] [Abstract][Full Text] [Related]
26. Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.
Narod SA; Dubé MP; Klijn J; Lubinski J; Lynch HT; Ghadirian P; Provencher D; Heimdal K; Moller P; Robson M; Offit K; Isaacs C; Weber B; Friedman E; Gershoni-Baruch R; Rennert G; Pasini B; Wagner T; Daly M; Garber JE; Neuhausen SL; Ainsworth P; Olsson H; Evans G; Osborne M; Couch F; Foulkes WD; Warner E; Kim-Sing C; Olopade O; Tung N; Saal HM; Weitzel J; Merajver S; Gauthier-Villars M; Jernstrom H; Sun P; Brunet JS
J Natl Cancer Inst; 2002 Dec; 94(23):1773-9. PubMed ID: 12464649
[TBL] [Abstract][Full Text] [Related]
27. Clinical and molecular characterization of BRCA-associated breast cancer: results from the DBCG.
Soenderstrup IMH; Laenkholm AV; Jensen MB; Eriksen JO; Gerdes AM; Hansen TVO; Kruse TA; Larsen MJ; Pedersen IS; Rossing M; Thomassen M; Ejlertsen B
Acta Oncol; 2018 Jan; 57(1):95-101. PubMed ID: 29164974
[TBL] [Abstract][Full Text] [Related]
28. BRCA1 germline mutations may be associated with reduced ovarian reserve.
Wang ET; Pisarska MD; Bresee C; Chen YD; Lester J; Afshar Y; Alexander C; Karlan BY
Fertil Steril; 2014 Dec; 102(6):1723-8. PubMed ID: 25256924
[TBL] [Abstract][Full Text] [Related]
29. Bias Explains Most of the Parent-of-Origin Effect on Breast Cancer Risk in BRCA1/2 Mutation Carriers.
Vos JR; Oosterwijk JC; Aalfs CM; Rookus MA; Adank MA; van der Hout AH; van Asperen CJ; Gómez Garcia EB; Mensenkamp AR; Jager A; Ausems MG; Mourits MJ; de Bock GH;
Cancer Epidemiol Biomarkers Prev; 2016 Aug; 25(8):1251-8. PubMed ID: 27277847
[TBL] [Abstract][Full Text] [Related]
30. Subfertility, use of fertility treatments and BRCA mutation status and the risk of ovarian cancer.
Lerner-Geva L; Chetrit A; Farhi A; Lubin F; Sadezki S;
Arch Gynecol Obstet; 2022 Jul; 306(1):209-217. PubMed ID: 35039881
[TBL] [Abstract][Full Text] [Related]
31. Breast cancer risk in BRCA1/2 mutation carriers and noncarriers under prospective intensified surveillance.
Engel C; Fischer C; Zachariae S; Bucksch K; Rhiem K; Giesecke J; Herold N; Wappenschmidt B; Hübbel V; Maringa M; Reichstein-Gnielinski S; Hahnen E; Bartram CR; Dikow N; Schott S; Speiser D; Horn D; Fallenberg EM; Kiechle M; Quante AS; Vesper AS; Fehm T; Mundhenke C; Arnold N; Leinert E; Just W; Siebers-Renelt U; Weigel S; Gehrig A; Wöckel A; Schlegelberger B; Pertschy S; Kast K; Wimberger P; Briest S; Loeffler M; Bick U; Schmutzler RK;
Int J Cancer; 2020 Feb; 146(4):999-1009. PubMed ID: 31081934
[TBL] [Abstract][Full Text] [Related]
32. Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations.
Rennert G; Bisland-Naggan S; Barnett-Griness O; Bar-Joseph N; Zhang S; Rennert HS; Narod SA
N Engl J Med; 2007 Jul; 357(2):115-23. PubMed ID: 17625123
[TBL] [Abstract][Full Text] [Related]
33. The yield of full BRCA1/2 genotyping in Israeli high-risk breast/ovarian cancer patients who do not carry the predominant mutations.
Barnes-Kedar I; Bernstein-Molho R; Ginzach N; Hartmajer S; Shapira T; Magal N; Kalis ML; Peretz T; Shohat M; Basel-Salmon L; Friedman E; Bazak L; Goldberg Y
Breast Cancer Res Treat; 2018 Nov; 172(1):151-157. PubMed ID: 30014164
[TBL] [Abstract][Full Text] [Related]
34. Antimüllerian hormone levels are lower in BRCA2 mutation carriers.
Johnson L; Sammel MD; Domchek S; Schanne A; Prewitt M; Gracia C
Fertil Steril; 2017 May; 107(5):1256-1265.e6. PubMed ID: 28476184
[TBL] [Abstract][Full Text] [Related]
35. BRCA1/2 gene mutations do not affect the capacity of oocytes from breast cancer candidates for fertility preservation to mature in vitro.
Grynberg M; Dagher Hayeck B; Papanikolaou EG; Sifer C; Sermondade N; Sonigo C
Hum Reprod; 2019 Feb; 34(2):374-379. PubMed ID: 30561604
[TBL] [Abstract][Full Text] [Related]
36. Prognostic Impact of Breast-Conserving Therapy Versus Mastectomy of BRCA1/2 Mutation Carriers Compared With Noncarriers in a Consecutive Series of Young Breast Cancer Patients.
van den Broek AJ; Schmidt MK; van 't Veer LJ; Oldenburg HSA; Rutgers EJ; Russell NS; Smit VTHBM; Voogd AC; Koppert LB; Siesling S; Jobsen JJ; Westenend PJ; van Leeuwen FE; Tollenaar RAEM
Ann Surg; 2019 Aug; 270(2):364-372. PubMed ID: 29727326
[TBL] [Abstract][Full Text] [Related]
37. Impact of Age at Primary Breast Cancer on Contralateral Breast Cancer Risk in BRCA1/2 Mutation Carriers.
van den Broek AJ; van 't Veer LJ; Hooning MJ; Cornelissen S; Broeks A; Rutgers EJ; Smit VT; Cornelisse CJ; van Beek M; Janssen-Heijnen ML; Seynaeve C; Westenend PJ; Jobsen JJ; Siesling S; Tollenaar RA; van Leeuwen FE; Schmidt MK
J Clin Oncol; 2016 Feb; 34(5):409-18. PubMed ID: 26700119
[TBL] [Abstract][Full Text] [Related]
38. Clinical outcome of breast cancer in carriers of BRCA1 and BRCA2 mutations according to molecular subtypes.
De Talhouet S; Peron J; Vuilleumier A; Friedlaender A; Viassolo V; Ayme A; Bodmer A; Treilleux I; Lang N; Tille JC; Chappuis PO; Buisson A; Giraud S; Lasset C; Bonadona V; Trédan O; Labidi-Galy SI
Sci Rep; 2020 Apr; 10(1):7073. PubMed ID: 32341426
[TBL] [Abstract][Full Text] [Related]
39. Hormone replacement therapy is more prevalent among Jewish BRCA1/2 mutation carriers.
Sade RB; Chetrit A; Figer A; Papa MZ; Flex D; Rizel S; Friedman E
Eur J Cancer; 2006 Mar; 42(5):650-5. PubMed ID: 16464572
[TBL] [Abstract][Full Text] [Related]
40. Earlier Age of Breast Cancer Onset in Israeli BRCA Carriers-Is it a Real Phenomenon?
Agranat S; Baris H; Kedar I; Shochat M; Rizel S; Perry S; Margel D; Sulkes A; Yerushalmi R
Breast J; 2016 Nov; 22(6):662-666. PubMed ID: 27533489
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]